Proliferation News and Research

RSS

Scientists discover molecular security mechanism for keeping gene mutations in check

Everyone knows mutations - genetic mistakes in DNA, the material of heredity - are bad: The more mutations in the cell's DNA, the higher the risk of cancer developing.

8 May 2006

Compensation by tumor suppressor genes during retinal development in mice and humans

Humans are more susceptible to developing the eye cancer retinoblastoma than mice because, unlike humans, mice can compensate for the loss of activity of a gene critical to normal retinal development, according to results of a study by investigators at St. Jude Children's Research Hospital.

3 May 2006

Lipoxin A4 regulates bronchial epithelial cell responses to acid injury

Doctors are gaining new leverage in the fight against lung injury caused by acid reflux. The paper by Bonnans et al., "Lipoxin A4 regulates bronchial epithelial cell responses to acid injury," appears in the April issue of The American Journal of Pathology and is accompanied by a commentary.

3 May 2006

Three-dimensional breast cell cultures reveal clues to breast cancer hidden inside stem cells

Stem cells and how to boost them is hot on the research agenda. But stopping them could be critical too, as evidence implicating stem cells in cancer is mounting.

3 May 2006

Protein made by cancer virus explains how the virus spreads

New research shows that a protein made by a cancer virus causes infected immune cells to cling to other immune cells, enabling the virus to spread.

26 Apr 2006

Blood cancers may be caused by inactivation of a "tumor suppressor" gene

The discovery of a gene, called PRDM1, as a tumor suppressor sheds new light on the cause - and possible treatment - of diffuse large B-cell lymphomas (DLBCLs), a cancer of the blood's B-lymphocytes. DLBCLs comprise about 30 percent of non-Hodgkin's lymphomas.

25 Apr 2006

Protein mutated in cancer found to be linked to diabetes

A study published by Nature has defined the function of p110 alpha, the flag-ship molecule of the eight member PI3K family, which is one of the most frequently activated pathways in cancer. The function of p110 alpha in the body has eluded researchers for over a decade but a new approach to generating mouse models, has allowed investigators to solve the mystery and yield important information for planned clinical trials with PI3K inhibitors.

25 Apr 2006

Imitating nature's scaffolding

A team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) has successfully created artificial fibers with nanometer-sized features that can be used to grow cells and tissue structures.

20 Apr 2006

miR 155 overexpression can lead to cancer

Scientists in the Ohio State University Comprehensive Cancer Center say that just one, single, malfunctioning microRNA is sufficient to cause cancer in mice.

18 Apr 2006

Genetic switch that links animal growth and cancer

Laboratory discoveries by scientists at two universities may lead to new directions in cancer therapy drugs. The researchers have discovered that a genetic switch involved in growth and development of an animal is the same one used to prevent normal cells from becoming cancerous.

18 Apr 2006

217 new targets for anti-cancer drugs

By identifying novel genes critical to cancer progression, biologists at the U.S. Department of Energy's Argonne National Laboratory have expanded the number of drug targets researchers have available for study to find ways to stop tumors in their tracks.

18 Apr 2006

Potent induction of chondrocytic differentiation of human adipose-derived adult stem cells by bone morphogenetic protein 6

A novel growth factor significantly improves the ability of specialized stem cells derived from human fat to be transformed into cartilage cells, according to Duke University Medical Center and Pratt School of Engineering researchers.

16 Apr 2006

Fat cells surrounding coronary arteries may play a role in development of heart disease

The fat cells that surround coronary arteries may play a central and previously unrecognized role in development of cardiovascular disease, according to a study by University of Iowa researchers.

11 Apr 2006

Lack of response to herceptin may be reversed with PI3K inhibiting agents

Breast cancer patients with HER2-positive tumors who don't respond to Herceptin (trastuzumab) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, say researchers at the University of Texas M. D. Anderson Cancer Center.

11 Apr 2006